The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

In the logistic regression model of the top 20 factors, significant associations for semaglutide initiation included being female (adjusted odds ratio, 2.30), using certain medication classes ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

The most reported signs were erythema, desquamation, dryness, and oozing affecting the face, neck, and upper extremities.

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke ...

In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.

The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...